BINEX Co., Ltd. (053030.KQ)
KRW 17490.0
(-3.95%)
KRW 17490.0
(-3.95%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 55.67 Billion KRW | 4.98% |
| 2022 | 53.03 Billion KRW | 13.36% |
| 2021 | 46.78 Billion KRW | 1.26% |
| 2020 | 46.2 Billion KRW | 3.25% |
| 2019 | 44.74 Billion KRW | 9.88% |
| 2018 | 40.72 Billion KRW | 14.73% |
| 2017 | 35.49 Billion KRW | 17.14% |
| 2016 | 30.3 Billion KRW | 16.71% |
| 2015 | 25.96 Billion KRW | 0.0% |
| 2013 | 22.66 Billion KRW | -25.88% |
| 2012 | 30.57 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 12.9 Billion KRW | -1.28% |
| 2024 Q2 | 13.41 Billion KRW | 5.47% |
| 2023 Q1 | 14.91 Billion KRW | -9.56% |
| 2023 Q2 | 14.51 Billion KRW | -2.68% |
| 2023 FY | 55.67 Billion KRW | 4.98% |
| 2023 Q3 | 13.33 Billion KRW | -8.1% |
| 2023 Q4 | 13.06 Billion KRW | -2.02% |
| 2022 Q4 | 16.49 Billion KRW | 35.52% |
| 2022 Q3 | 12.16 Billion KRW | -3.11% |
| 2022 Q2 | 12.55 Billion KRW | 8.12% |
| 2022 FY | 53.03 Billion KRW | 13.36% |
| 2022 Q1 | 11.61 Billion KRW | -6.44% |
| 2021 Q1 | 11.63 Billion KRW | -48.4% |
| 2021 Q2 | 12 Billion KRW | 3.16% |
| 2021 Q3 | 10.72 Billion KRW | -10.71% |
| 2021 Q4 | 12.41 Billion KRW | 15.8% |
| 2021 FY | 46.78 Billion KRW | 1.26% |
| 2020 Q2 | 9.85 Billion KRW | -17.16% |
| 2020 Q3 | 11.24 Billion KRW | 14.2% |
| 2020 Q4 | 22.55 Billion KRW | 100.52% |
| 2020 FY | 46.2 Billion KRW | 3.25% |
| 2020 Q1 | 11.89 Billion KRW | 3.68% |
| 2019 Q4 | 11.46 Billion KRW | 4.91% |
| 2019 Q2 | 11.24 Billion KRW | 5.23% |
| 2019 Q1 | 10.68 Billion KRW | 12.83% |
| 2019 FY | 44.74 Billion KRW | 9.88% |
| 2019 Q3 | 10.93 Billion KRW | -2.79% |
| 2018 Q2 | 11.65 Billion KRW | 16.48% |
| 2018 FY | 40.72 Billion KRW | 14.73% |
| 2018 Q4 | 9.47 Billion KRW | -11.99% |
| 2018 Q3 | 10.76 Billion KRW | -7.64% |
| 2018 Q1 | 10 Billion KRW | -14.35% |
| 2017 FY | 35.49 Billion KRW | 17.14% |
| 2017 Q3 | 9.15 Billion KRW | -2.09% |
| 2017 Q2 | 9.34 Billion KRW | 12.1% |
| 2017 Q4 | 11.67 Billion KRW | 27.61% |
| 2017 Q1 | 8.33 Billion KRW | 18.89% |
| 2016 Q2 | 7.89 Billion KRW | -3.31% |
| 2016 Q3 | 8.18 Billion KRW | 3.73% |
| 2016 Q4 | 7.01 Billion KRW | -14.35% |
| 2016 FY | 30.3 Billion KRW | 16.71% |
| 2016 Q1 | 8.16 Billion KRW | -44.03% |
| 2015 Q1 | 6.35 Billion KRW | 0.0% |
| 2015 Q4 | 14.58 Billion KRW | 115.11% |
| 2015 FY | 25.96 Billion KRW | 0.0% |
| 2015 Q3 | 6.78 Billion KRW | 1.18% |
| 2015 Q2 | 6.7 Billion KRW | 5.41% |
| 2014 Q1 | 5.75 Billion KRW | -19.06% |
| 2014 Q2 | 6.58 Billion KRW | 14.37% |
| 2014 Q3 | 5.09 Billion KRW | -22.58% |
| 2013 Q4 | 7.11 Billion KRW | 21.46% |
| 2013 Q1 | 4.5 Billion KRW | -62.77% |
| 2013 Q3 | 5.85 Billion KRW | 14.44% |
| 2013 Q2 | 5.11 Billion KRW | 13.45% |
| 2013 FY | 22.66 Billion KRW | -25.88% |
| 2012 Q3 | 6.5 Billion KRW | 0.0% |
| 2012 Q4 | 12.11 Billion KRW | 86.04% |
| 2012 FY | 30.57 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Co., Ltd. | 109.98 Billion KRW | 49.38% |
| iNtRON Biotechnology, Inc. | 7.84 Billion KRW | -609.622% |
| Bioneer Corporation | 204.55 Billion KRW | 72.783% |
| Anterogen.Co.,Ltd. | 7.74 Billion KRW | -619.307% |
| MEDIPOST Co., Ltd. | 65.31 Billion KRW | 14.758% |
| CrystalGenomics, Inc. | 32.36 Billion KRW | -71.998% |
| Helixmith Co., Ltd | 37.36 Billion KRW | -48.996% |
| Chabiotech Co.,Ltd. | 285.93 Billion KRW | 80.529% |
| Medy-Tox Inc. | 110.88 Billion KRW | 49.79% |
| Peptron, Inc. | 16.65 Billion KRW | -234.257% |
| Amicogen, Inc. | 52.82 Billion KRW | -5.4% |
| Genexine, Inc. | 41.62 Billion KRW | -33.745% |
| HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | -244.39% |
| LegoChem Biosciences, Inc. | 98.61 Billion KRW | 43.545% |
| ALTEOGEN Inc. | 40.93 Billion KRW | -36.009% |
| PharmaResearch Co., Ltd. | 89.44 Billion KRW | 37.751% |
| SillaJen, Inc. | 5.11 Billion KRW | -989.066% |
| JETEMA, Co., Ltd. | 25.66 Billion KRW | -116.938% |
| OliX Pharmaceuticals,Inc | 35.24 Billion KRW | -57.947% |
| Genomictree Inc. | 16.26 Billion KRW | -242.306% |
| MedPacto, Inc. | 26.91 Billion KRW | -106.824% |
| D&D Pharmatech | 32.16 Billion KRW | -73.103% |
| EASY BIO,Inc. | 29.67 Billion KRW | -87.638% |
| GI Innovation, Inc. | 57.59 Billion KRW | 3.329% |